# Third Arc Bio

> Clinical-stage biotechnology company developing multifunctional antibodies that build immune
> synapses to precisely activate or inhibit T cells. Platforms: ARCStim (solid tumors) and ARCTag
> (immunology & inflammation). Lead program ARC101, a bispecific T-cell engager, is in Phase 1 in
> patients with CLDN6-expressing solid tumors.

## Developer surface

Third Arc Bio publishes NO public API. As of 2026-08-30 there is no developer portal, no API
reference, no OpenAPI/AsyncAPI/GraphQL/Protobuf/WSDL contract, no SDK or package in any public
registry, no MCP server, no A2A agent card, and no /.well-known/ document on thirdarcbio.com.
The only host that resolves is thirdarcbio.com (a Gatsby static site backed by Sanity CMS);
api., developer., docs. and mcp. subdomains do not resolve. This is an honest zero, not a gap in
our probing — therapeutics, not software, is the product.

## Pages

- [Home](https://thirdarcbio.com/): company overview
- [Our Science](https://thirdarcbio.com/our-science/): ARCStim and ARCTag platforms
- [Our Pipeline](https://thirdarcbio.com/our-pipeline/): programs and development stage
- [Our Team](https://thirdarcbio.com/our-team/): leadership, board, scientific advisors, investors
- [News](https://thirdarcbio.com/news/): press releases
- [Privacy Policy](https://thirdarcbio.com/privacy-policy/)
- [Terms of Service](https://thirdarcbio.com/terms-of-service/)

## Contact

- info@thirdarcbio.com
- [LinkedIn](https://www.linkedin.com/company/third-arc-bio/)

## About this file

Generated by the API Evangelist enrichment pipeline from a public probe of thirdarcbio.com.
It is not published by Third Arc Bio. method: generated. source: apis.yml + live probes.